Inventor(s): Alexander Gaiger et al.

Express Mail No. EV741777884US "REPLACEMENT SHEET"

APR 2 8 2006 W

HU: MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSL MO: MGSDVRDLNALLPAVSSLGGGGGCGLPVSGAAQWAPVLDFAPPGASAYGSL

HU: GGPAPPPAPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAG MO: GGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTLHFSGQFTGTAG

HU: ACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPS MO: ACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPTIRNQGYSTVTFDGAPS

HU: YGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTG MO: YGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTG

HU: SQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTE MO: SQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGMAAGSSSSVKWTE

HU: GQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSAS MO: GQSNHGIGYESDNHTAPILCGAQYRIHTHGVFRGIQDVRRVSGVAPTLVRSAS

HU: ETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSR MO: ETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSR

HU: SDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCR MO: SDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCR

HU: WPSCQKKFARSDELVRHHNMHQRNMTKLQLAL MO: WHSCQKKFARSDELVRHHNMHQRNMTKLHVAL




Fig. 2




Fig. 3





Fig. 4






Fig. 5C

Vaccine A stimulated line

Vaccine B stimulated line




Fig. 6A

Fig. 6B

Serial No. 09/684,361 Docket No. 210121.465C2
Inventor(s): Alexander Gaiger et al.
Express Mail No. EV741777884US "REPLACEMENT SHEET"

p117-139 stimulated line

p117-139 stimulated clone




Fig. 7A




Fig. 7B

p6-22 stimulated line

p6-22 stimulated clone




Fig. 7C




Fig. 7D

MGSD	VRDI	LNAL	LPAVI	20 PSLGG@ VAAAAA	GGCAL	.PVSGA	AQWAP	VLDFA	PPGAS	AYGSL	.GGPAP	PPAPP	PPPPP	PPHSF	IKQE
						RR	RR								
				۰۰۰۰۰											
PSWG(	AEI	PHEE	QCLS/	95 AFTVHF VAA	SGQFT AA	GTAGA AA	CRYGP	FGPPP	PSQAS 	SGQAR AA	MFPNA A	PYLPS AAA	CLESQ AAA	PAIRN	QGYS 
									DDDDD	DDDD.					
TVTF	OGTI	PSYG 	HTPSI	170 HAAQF AAAAA RRRR.	PNHSF	KHEDP	MGQQG	SLGEQ	QYSVP	PPVYO	CHTPT AAAAA	DSCTG A	SQALL	LRTPY	SSDN AA
												DDDI	DDDDDI	ODDDDI	D
LYQMT AAAAA 	rsqi Vaa · · · ·	ECM 4	TWNQN	245 Inlgat  Rrr	LKGVA VAA . AA RRRRR	AGSSS VA RR	SVKWT	EGQSN 	HSTGY 	ESDNH	ITTPIL	CGAQY	RIHTH AA	GVFRG AAAAA RRRR .	IQDV AAAA 
				• • • • •											
RRVPG AAAA/ R	SVAF A/ RRR D	PTLV NAAA IR IDDDI	RSASE AAAA  DD	320 ETSEKR WAA	PFMCA	YPGCN	KRYFK  .RRRR	LSHLQ	MHSRK	HTGEK	PYQCD	FKDCE A	RRFSR AAA . A	SDQLK AAAAA	RHQR AAA .
RHTGV	/KPF 	QCK	TCQRK AAA	395 (FSRSD A.AAA	HLKTH AAA	TRTHT	GKTSE AAAA 	KPFSC	RWPSC A	QKKFA 4a RRR	RSDEL .aaaa Rrri	VRHHNI AAAA RR	MHQRN AAA	MTKLQ	LAL
	• • •	• • •	<i>.</i>				• • • • •	• • • • •		• • • • •	• • • • •	• • • • •		• • • • •	

	SDVRD AA	LNALI	_PAVS! vaaav	SLGGG Vaaaa	GGCGL A	PVSGA AA	35 AQWAP AAAA RR	VLDF <i>A</i>	APPGAS AA	aygsl Aaaaa	.GGPAP Aaaaa		PPPPP 	PPHSF	IKQE
PSI	80 NGGAE	85 PHEEC	90 QCLSAI	95 FTLHF	100 SGQFT AA	105 GTAGA AA RRRR.	110 CRYGP	115 FGPPP	120 PSQAS	 125 SGQAR AA R	130 MFPNA A RRRR.	 135 PYLPS AAA	140 CLESQ AAA	145 PTIRN	150 QGYS
TV	155 TFDGA	160 PSYGH	165 HTPSHI F	170 HAAQF VAAAA RRRR	175 PNHSF	180 KHEDF	185 MGQQG	190 SLGEC	195 QYSVP	200 PPVY6	205 CHTPT AAAAA	210 DSCTG A	215 SQALL	220 LRTPY	225 SSDN AA 
LY(	230 QMTSQ AAAAA 	235 LECMT A	240   WNQMI	245 NLGATI A RRRF	250 LKGMA AA.AA RRRRRI DDDDD	255 AGSSS A RR	260 SVKWT  RRRI D	265 EGQSN 	270 HGIGY	.275 ESDNH	280 TAPIL	285 CGAQY	290 RIHTH AA	295 GVFRG AAAAA RRRR.	300 IQDV AAAA
RR\ AA/ 	305 /SGVA VAA . RRRI IDDDDI	310 PTLVF AAAA/ RR DDDDD	315 RSASET VAAAA  D	320 TSEKRI	325 PFMCA	330 YPGCN	335 KRYFK  .RRRR	340 LSHLQ	345 MHSRK 	350 HTGEK	355 PYQCD	360 FKDCE A	365 RRFSR AAA . A	370 SDQLKI AAAAA	375 RHQR AAA .
RH1	GVKPI	FQCKT	CQRKI	FSRSDI N. AAAA	ILKTH 1 AA	TRTHT	410 GKTSE AAAA	KPFSC	RWHSC	QKKFA 4A RRRI	RSDEL . AAAA R RRI	VRHHN 4444. RR	MHQRN AAA	MTKLH A	VAL




Fig. 9A




Fig. 9B




Fig. 10A




Fig. 10B





Fig. 10C











Fig. 10D

















Fig. 13C




Fig. 14




Fig. 15

"REPLACEMENT SHEET"

Express Mail No. EV741777884US




Fig. 16




Fig. 17

Serial No. 09/684,361 Docket No. 210121.465C2
Inventor(s): Alexander Gaiger et al

Inventor(s): Alexander Gaiger et al.
Express Mail No. EV741777884US "REPLACEMENT SHEET"

Characteristics of Recombinant WT1 Proteins Used for Serological Analysis

NAME	Recombinant Protein	WT1 Amino Acid Position	<u>Molecular Weight</u>
WT1/full-length	Ral2—WT1 full length fusion protein	aa 1—449	85kDa
WT1/N-terminus	TRX—WT1 N—terminus fusion protein	aa 1—249	60kDa
WT1/C-terminus	WT1 C-terminus protein	aa 267-449	50kDa

Fig. 18

WT1 Specific Serum Antibodies in Patients with AML and CML

WT1/C-terminus	1/96 (1%)	2/63 (3%)	3/81 (3%)
WT1/N-terminus	1/96 (1%)	16/63 (25%)	12/81 (15%)
WT1/full-length	2/96 (2%)	14/63 (22%)	15/81 (19%)
	Normal Individials (n=96)	AML Patients (n=63)	CML Patients (n=81)

Fig. 15